ClinicalTrials.gg
TerminatedNCT06065124BEAT-ITUpdated Nov 12, 2026

Bariatric Surgery Evaluation and Assessment of Treatment Efficacy - Intervention Trial

An interventional study of Bariatric surgery strategy in Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation, sponsored by University Medical Center Groningen. Terminated at 2 sites in Netherlands. Open to participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
slow patient inclusion
Updated Nov 12, 2026Now TerminatedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Atrial Fibrillation by University Medical Center Groningen — 3 open to participants now, 3 under way, none of them phase 3. Atrial Fibrillation · University Medical Center Groningen.

Enrollment
12th of 13
1 · median 220
Started
2024
with 3 others
No phase
9 of 16
3 open now
Registered
12th of 16
by date

Among the 16 studies in Atrial Fibrillation by University Medical Center Groningen, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2024, is one of 9 with no phase, and was the 12th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 16 studies in Atrial Fibrillation by University Medical Center Groningen are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 45 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Atrial Fibrillation by University Medical Center Groningen, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate if a bariatric surgery strategy will improve clinical endpoints, cardiac parameters and functional status in patients with obesity (with BMI 32-40 kg/m2) and symptomatic HF with preserved or mildly reduced LVEF in combination with AF, as compared to standard of care. Patients will be randomized to either the Intervention group receiving bariatric surgery including an intensive pre- and postoperative treatment scheme or to the control group receiving standard of care.

Read the detailed description

The primary objective is to study the effect of a bariatric surgery strategy on the hierarchical occurrence of: 1) all-cause mortality within 2 years, 2) emergency room visit or hospitalization for HF within 2 years, 3) recurrent ECG-documented AF within 2 years, 4) decrease of ≥30gr of left ventricular (LV) mass on transthoracic echocardiography, and 5) improvement of ≥5 points on the Kansas City Cardiomyopathy Questionnaire (KCCQ).

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction
  • Atrial Fibrillation

Browse trials for

Keywords

  • Atrial Fibrillation
  • Heart Failure with Preserved Ejection Fraction
  • Bariatric surgery
04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signs and symptoms of HF according to the Europeans Society of Cardiology guideline;
  2. ≥40%;
  3. HFA-PEFF score ≥5 or HFA-PEFF score 2-4 in combination with positive stress test;
  4. Between 45 and 70 years of age;
  5. 32-40 kg/m2;
  6. Paroxysmal or persistent AF with a rhythm control strategy;
  7. Willing to undergo both treatment strategies;
  8. Written .

Exclusion criteria

Exclusion Criteria:

  1. ≥40 kg/m2;
  2. BMI \<32 kg/m2;
  3. Patients unwilling or unable to sign ;
  4. More than moderate mitral valve regurgitation/aortic valve regurgitation;
  5. More than mild mitral valve stenosis/aortic valve stenosis;
  6. Inadequate echocardiographic window for the assessment of LV mass index and/or the echocardiographic criteria needed for the HFA-PEFF score;
  7. History of myocardial infarction, myocarditis, any invasive cardiac intervention (e.g. surgery, percutaneous coronary intervention, ablation) or stroke, \<3 months before inclusion;
  8. Scheduled for AF ablation;
  9. Complex congenital heart disease;
  10. Negative treatment advise from a specialized psychiatrist due to non-stabilized psychotic disorders, severe depression and/or personality disorders;
  11. Patients unable to care for themselves or who are unable adapt to inherent lifestyle changes following bariatric surgery;
  12. Any medical condition that limits life span \<2 years;
  13. Diseases requiring long term use of anti-inflammatory treatments;
  14. The use of medication associated with substantial effects (>5 kg) on body weight.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Active comparator
    Bariatric surgery strategy

    The intervention group will receive bariatric surgery including an intensive pre- and postoperative treatment scheme

    Procedure: Bariatric surgery strategy

  • No intervention
    Standard of Care

    The control group will receive standard of care

Interventions

  • ProcedureBariatric surgery strategy

    Bariatric surgery including an intensive pre- and postoperative treatment scheme

06

What researchers measure

Primary outcomes

  1. Hierarchical endpoint

    The hierarchical occurrence of: 1) All-cause mortality; 2) Emergency room visit or hospitalization for HF; 3) Recurrent ECG-documented AF; 4) Decrease of ≥30gr of LV mass on transthoracic echocardiography; 5) Improvement of ≥5 points on the Kansas City Cardiomyopathy Questionnaire (Scores are transformed to a range of 0-100, in which higher scores reflect better health status)

    Time frame: 2 years

Secondary outcomes

  1. All-cause mortality

    All-cause mortality

    Time frame: 2 years

  2. Emergency room visit or hospitalization for HF

    Emergency room visit or hospitalization for HF

    Time frame: 2 years

  3. Rate of recurrent AF

    Recurrent AF documented on ECG

    Time frame: 2 years

  4. Decrease of left ventricular mass

    Decrease of ≥30gr of LV mass measured by transthoracic echocardiography

    Time frame: 2 years

  5. Kansas City Cardiomyopathy Questionnaire improvement

    Improvement of ≥5 points on the Kansas City Cardiomyopathy Questionnaire (scores are transformed to a range of 0-100, in which higher scores reflect better health status)

    Time frame: 2 years

Other outcomes

  1. Weight reduction

    Measuring weight during clinical trial

    Time frame: 2 years

  2. Medication changes after surgery

    Medication changes after surgery

    Time frame: 2 years

  3. Concomitant cardiovascular conditions and relevant comorbidities

    Medical history of patient

    Time frame: 2 years

  4. Change in left atrial volume

    Change in left atrial volume measured by transthoracic echocardiography

    Time frame: 2 years

  5. Change in left ventricular diastolic dysfunction

    Change in left ventricular diastolic dysfunction measured by transthoracic echocardiography with the definition according to the leading guidelines

    Time frame: 2 years

  6. Change in left ventricular ejection fraction

    Change in left ventricular ejection fraction measured by transthoracic echocardiography

    Time frame: 2 years

  7. Change in right ventricular function

    Change in right ventricular function measured by transthoracic echocardiography with the definition according to the leading guidelines

    Time frame: 2 years

  8. Change in diameter of epicardial fat

    Change in diameter of epicardial fat measured by transthoracic echocardiography

    Time frame: 2 years

  9. Healthcare resource use/costs

    Measured with the iMedical Consumption Questionnaire (instrument for measuring medical consumption, costs will be estimated by given answers and relation to known costs of the items of medical consumption)

    Time frame: 2 years

  10. Health related quality of life / utility

    Measured with the 5-level EQ-5D questionnaire (The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression)

    Time frame: 2 years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2024 to primary completion in Aug 2026, 25 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2027 → Aug 2026 and completion Oct 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2023
First posted
Oct 3, 2023
StartActual
Jul 1, 2024
Primary completionActual
Aug 1, 2026was Oct 2027
CompletionActual
Aug 1, 2026was Oct 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated slow patient inclusion
changed Nov 12, 2026
Sites
1 site added, 1 site removed
Show site
  • University Medical Center Groningen · Groningen, Netherlands
Show 1 removed
  • University Medical Center Groningen · Groningen, Netherlands
Nov 12, 2026
Primary completion
Oct 2027→Aug 1, 2026 (actual)
Nov 12, 2026
Study completion
Oct 2027→Aug 1, 2026 (actual)
Nov 12, 2026
Enrollment
108 (estimated)→1 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Terminated
    Why stopped slow patient inclusion
    1 site added, 1 site removed
    Show site
    • University Medical Center Groningen · Groningen, Netherlands
    Show 1 removed
    • University Medical Center Groningen · Groningen, Netherlands
    Primary completion Oct 2027→Aug 1, 2026 (now actual)
    Study completion Oct 2027→Aug 1, 2026 (now actual)
    Enrollment 108 (estimated)→1 (actual)
    + 3 other changes: identifiers, conditions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06065124
Collaborators
Rijnstate Hospital
Responsible party
Sponsor
First posted
Oct 3, 2023
Start date
Jul 1, 2024
Primary completion
Aug 1, 2026
Completion
Aug 1, 2026
Last update
Nov 12, 2026

Study contacts

Michiel Rienstra, MD, PhD
principal investigator · University Medical Center Groningen
Dirk Jan van Veldhuisen, MD, PhD
principal investigator · University Medical Center Groningen
Thomas M Gorter, MD, PhD
principal investigator · University Medical Center Groningen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion